Voor wie we er zijnOnze wetenschapProductenResultaten
InloggenVraagAan de slagvanaf $ 449
Kenmerk
Blood in urine
Klinische naam: Hematuria
The presence of blood in the urine. Hematuria may be gross hematuria (visible to the naked eye) or microscopic hematuria (detected by dipstick or microscopic examination of the urine).
Samenvatting
- Ook bekend als
- High urine occult blood
Blood in urineHP:0000790
Voor wie we er zijnOnze wetenschapProductenResultaten
InloggenVraagAan de slagvanaf $ 449
Read the genes linked to Blood in urine, and the rest of your genome, with one test.
Vanaf $ 449Gratis verzending · Resultaten binnen 6–8 weken
Mijn Genome Test bestellen163 genen gekoppeld aan Blood in urine
Veranderingen in deze genen veroorzaken zeldzame aandoeningen waarbij Blood in urine voorkomt. De meeste mensen met dit kenmerk hebben geen van die aandoeningen, en een gen op deze lijst zegt niets over het eigen genoom van iemand.
| Gen | Hoe vaak het voorkomt | Aandoeningen |
|---|---|---|
| APRTadenine phosphoribosyltransferase | Altijd | In 1 aandoening |
| CTNScystinosin, lysosomal cystine transporter | Altijd | In 1 aandoening |
| HMOX1heme oxygenase 1 | Altijd | In 1 aandoening |
| IFT140intraflagellar transport 140 | Altijd | In 2 aandoeningen |
| LAMB2laminin subunit beta 2 | Altijd | In 1 aandoening |
| LARS2leucyl-tRNA synthetase 2, mitochondrial | Altijd | In 1 aandoening |
| MCCC1methylcrotonyl-CoA carboxylase subunit 1 | Altijd | In 1 aandoening |
| MYO1Emyosin IE | Altijd | In 1 aandoening |
| PLD4phospholipase D family member 4 | Altijd | In 1 aandoening |
| COL4A3collagen type IV alpha 3 chain | Heel vaak (80–99%) | In 3 aandoeningen |
| COL4A4collagen type IV alpha 4 chain | Heel vaak (80–99%) | In 4 aandoeningen |
| CTLA4cytotoxic T-lymphocyte associated protein 4 | Heel vaak (80–99%) | In 2 aandoeningen |
| GLAgalactosidase alpha | Heel vaak (80–99%) | In 1 aandoening |
| HLA-DPA1major histocompatibility complex, class II, DP alpha 1 | Heel vaak (80–99%) | In 1 aandoening |
| HLA-DPB1major histocompatibility complex, class II, DP beta 1 | Heel vaak (80–99%) | In 1 aandoening |
| HOGA14-hydroxy-2-oxoglutarate aldolase 1 | Heel vaak (80–99%) | In 1 aandoening |
| PRTN3proteinase 3 | Heel vaak (80–99%) | In 1 aandoening |
| PTPN22protein tyrosine phosphatase non-receptor type 22 | Heel vaak (80–99%) | In 3 aandoeningen |
| AGXTalanine--glyoxylate aminotransferase | Vaak (30–79%) | In 2 aandoeningen |
| ALG5ALG5 dolichyl-phosphate beta-glucosyltransferase | Vaak (30–79%) | In 1 aandoening |
| ALG9ALG9 alpha-1,2-mannosyltransferase | Vaak (30–79%) | In 1 aandoening |
| BANK1B cell scaffold protein with ankyrin repeats 1 | Vaak (30–79%) | In 1 aandoening |
| BICC1BicC family RNA binding protein 1 | Vaak (30–79%) | In 1 aandoening |
| BLKBLK proto-oncogene, Src family tyrosine kinase | Vaak (30–79%) | In 1 aandoening |
| C4Acomplement C4A (Chido/Rodgers blood group) | Vaak (30–79%) | In 1 aandoening |
| C4Bcomplement C4B (Chido/Rodgers blood group) | Vaak (30–79%) | In 1 aandoening |
| CLDN19claudin 19 | Vaak (30–79%) | In 1 aandoening |
| COL4A1collagen type IV alpha 1 chain | Vaak (30–79%) | In 2 aandoeningen |
| COL4A5collagen type IV alpha 5 chain | Vaak (30–79%) | In 1 aandoening |
| COL4A6collagen type IV alpha 6 chain | Vaak (30–79%) | In 1 aandoening |
| CR2complement C3d receptor 2 | Vaak (30–79%) | In 1 aandoening |
| DGKEdiacylglycerol kinase epsilon | Vaak (30–79%) | In 1 aandoening |
| DNAJB11DnaJ heat shock protein family (Hsp40) member B11 | Vaak (30–79%) | In 1 aandoening |
| DNASE1deoxyribonuclease 1 | Vaak (30–79%) | In 1 aandoening |
| DNASE1L3deoxyribonuclease 1L3 | Vaak (30–79%) | In 1 aandoening |
| ETS1ETS proto-oncogene 1, transcription factor | Vaak (30–79%) | In 1 aandoening |
| FCGR2BFc gamma receptor IIb | Vaak (30–79%) | In 1 aandoening |
| FCGR3BFc gamma receptor IIIb | Vaak (30–79%) | In 1 aandoening |
| GANABglucosidase II alpha subunit | Vaak (30–79%) | In 1 aandoening |
| HLA-DRB1major histocompatibility complex, class II, DR beta 1 | Vaak (30–79%) | In 2 aandoeningen |
Toon nog 123 genen
| Gen | Hoe vaak het voorkomt | Aandoeningen |
|---|---|---|
| HNF1BHNF1 homeobox B | Vaak (30–79%) | In 1 aandoening |
| HPRT1hypoxanthine phosphoribosyltransferase 1 | Vaak (30–79%) | In 1 aandoening |
| IGHG1immunoglobulin heavy constant gamma 1 (G1m marker) | Vaak (30–79%) | In 1 aandoening |
| IL10interleukin 10 | Vaak (30–79%) | In 1 aandoening |
| IRAK1interleukin 1 receptor associated kinase 1 | Vaak (30–79%) | In 2 aandoeningen |
| IRF5interferon regulatory factor 5 | Vaak (30–79%) | In 1 aandoening |
| ITGA6integrin subunit alpha 6 | Vaak (30–79%) | In 1 aandoening |
| ITGAMintegrin subunit alpha M | Vaak (30–79%) | In 1 aandoening |
| ITGB4integrin subunit beta 4 | Vaak (30–79%) | In 1 aandoening |
| JAZF1JAZF zinc finger 1 | Vaak (30–79%) | In 1 aandoening |
| KANK2KN motif and ankyrin repeat domains 2 | Vaak (30–79%) | In 1 aandoening |
| KIAA0319LKIAA0319 like | Vaak (30–79%) | In 1 aandoening |
| MECP2methyl-CpG binding protein 2 | Vaak (30–79%) | In 1 aandoening |
| NEK8NIMA related kinase 8 | Vaak (30–79%) | In 1 aandoening |
| PAX2paired box 2 | Vaak (30–79%) | In 1 aandoening |
| PDCD1programmed cell death 1 | Vaak (30–79%) | In 1 aandoening |
| PFKMphosphofructokinase, muscle | Vaak (30–79%) | In 1 aandoening |
| PKD1polycystin 1, transient receptor potential channel interacting | Vaak (30–79%) | In 1 aandoening |
| PKD2polycystin 2, transient receptor potential cation channel | Vaak (30–79%) | In 1 aandoening |
| PXKPX domain containing serine/threonine kinase like | Vaak (30–79%) | In 1 aandoening |
| SAT1spermidine/spermine N1-acetyltransferase 1 | Vaak (30–79%) | In 1 aandoening |
| SERPINF2serpin family F member 2 | Vaak (30–79%) | In 1 aandoening |
| SLC7A7solute carrier family 7 member 7 | Vaak (30–79%) | In 1 aandoening |
| SPP1secreted phosphoprotein 1 | Vaak (30–79%) | In 2 aandoeningen |
| SPRY2sprouty RTK signaling antagonist 2 | Vaak (30–79%) | In 1 aandoening |
| STAT4signal transducer and activator of transcription 4 | Vaak (30–79%) | In 2 aandoeningen |
| STIM1stromal interaction molecule 1 | Vaak (30–79%) | In 1 aandoening |
| TLR7toll like receptor 7 | Vaak (30–79%) | In 1 aandoening |
| TNFAIP3TNF alpha induced protein 3 | Vaak (30–79%) | In 1 aandoening |
| TNFSF4TNF superfamily member 4 | Vaak (30–79%) | In 1 aandoening |
| TNIP1TNFAIP3 interacting protein 1 | Vaak (30–79%) | In 1 aandoening |
| TREX1three prime repair exonuclease 1 | Vaak (30–79%) | In 2 aandoeningen |
| TSC1TSC complex subunit 1 | Vaak (30–79%) | In 1 aandoening |
| TSC2TSC complex subunit 2 | Vaak (30–79%) | In 1 aandoening |
| UBE2L3ubiquitin conjugating enzyme E2 L3 | Vaak (30–79%) | In 1 aandoening |
| YAP1Yes1 associated transcriptional regulator | Vaak (30–79%) | In 2 aandoeningen |
| ACP5acid phosphatase 5, tartrate resistant | Soms (5–29%) | In 1 aandoening |
| AGGF1angiogenic factor with G-patch and FHA domains 1 | Soms (5–29%) | In 1 aandoening |
| BNC2basonuclin zinc finger protein 2 | Soms (5–29%) | In 1 aandoening |
| CD109CD109 molecule | Soms (5–29%) | In 1 aandoening |
| CLEC7AC-type lectin domain containing 7A | Soms (5–29%) | In 1 aandoening |
| DLSTdihydrolipoamide S-succinyltransferase | Soms (5–29%) | In 1 aandoening |
| DNMT3ADNA methyltransferase 3 alpha | Soms (5–29%) | In 1 aandoening |
| DPH1diphthamide biosynthesis 1 | Soms (5–29%) | In 1 aandoening |
| EPAS1endothelial PAS domain protein 1 | Soms (5–29%) | In 1 aandoening |
| F10coagulation factor X | Soms (5–29%) | In 1 aandoening |
| F5coagulation factor V | Soms (5–29%) | In 1 aandoening |
| F8coagulation factor VIII | Soms (5–29%) | In 1 aandoening |
| F9coagulation factor IX | Soms (5–29%) | In 1 aandoening |
| FAN1FANCD2 and FANCI associated nuclease 1 | Soms (5–29%) | In 1 aandoening |
| FCGR2CFc gamma receptor IIc (gene/pseudogene) | Soms (5–29%) | In 1 aandoening |
| FHfumarate hydratase | Soms (5–29%) | In 1 aandoening |
| GBA1glucosylceramidase beta 1 | Soms (5–29%) | In 2 aandoeningen |
| GP1BAglycoprotein Ib platelet subunit alpha | Soms (5–29%) | In 1 aandoening |
| GP1BBglycoprotein Ib platelet subunit beta | Soms (5–29%) | In 1 aandoening |
| HLA-Bmajor histocompatibility complex, class I, B | Soms (5–29%) | In 1 aandoening |
| IL17Finterleukin 17F | Soms (5–29%) | In 1 aandoening |
| IL17RAinterleukin 17 receptor A | Soms (5–29%) | In 1 aandoening |
| IL17RCinterleukin 17 receptor C | Soms (5–29%) | In 1 aandoening |
| ITGA2integrin subunit alpha 2 | Soms (5–29%) | In 1 aandoening |
| ITGA2Bintegrin subunit alpha 2b | Soms (5–29%) | In 1 aandoening |
| ITGB3integrin subunit beta 3 | Soms (5–29%) | In 1 aandoening |
| KIF1Bkinesin family member 1B | Soms (5–29%) | In 1 aandoening |
| LMAN1lectin, mannose binding 1 | Soms (5–29%) | In 1 aandoening |
| LMX1BLIM homeobox transcription factor 1 beta | Soms (5–29%) | In 2 aandoeningen |
| MAXMYC associated transcriptional regulator X | Soms (5–29%) | In 1 aandoening |
| MCFD2multiple coagulation factor deficiency 2, ER cargo receptor complex subunit | Soms (5–29%) | In 1 aandoening |
| MDH2malate dehydrogenase 2 | Soms (5–29%) | In 1 aandoening |
| NF1neurofibromin 1 | Soms (5–29%) | In 1 aandoening |
| OCRLOCRL inositol polyphosphate-5-phosphatase | Soms (5–29%) | In 1 aandoening |
| P4HA2prolyl 4-hydroxylase subunit alpha 2 | Soms (5–29%) | In 1 aandoening |
| PIK3CAphosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha | Soms (5–29%) | In 1 aandoening |
| RETret proto-oncogene | Soms (5–29%) | In 2 aandoeningen |
| SCARB2scavenger receptor class B member 2 | Soms (5–29%) | In 1 aandoening |
| SDHAsuccinate dehydrogenase complex flavoprotein subunit A | Soms (5–29%) | In 1 aandoening |
| SDHAF2succinate dehydrogenase complex assembly factor 2 | Soms (5–29%) | In 1 aandoening |
| SDHBsuccinate dehydrogenase complex iron sulfur subunit B | Soms (5–29%) | In 2 aandoeningen |
| SDHCsuccinate dehydrogenase complex subunit C | Soms (5–29%) | In 1 aandoening |
| SDHDsuccinate dehydrogenase complex subunit D | Soms (5–29%) | In 2 aandoeningen |
| SLC22A12solute carrier family 22 member 12 | Soms (5–29%) | In 1 aandoening |
| SLC25A11solute carrier family 25 member 11 | Soms (5–29%) | In 1 aandoening |
| SLC2A9solute carrier family 2 member 9 | Soms (5–29%) | In 1 aandoening |
| SREBF1sterol regulatory element binding transcription factor 1 | Soms (5–29%) | In 1 aandoening |
| TMEM127transmembrane protein 127 | Soms (5–29%) | In 1 aandoening |
| TRAF3IP2TRAF3 interacting protein 2 | Soms (5–29%) | In 1 aandoening |
| UMODuromodulin | Soms (5–29%) | In 1 aandoening |
| VHLvon Hippel-Lindau tumor suppressor | Soms (5–29%) | In 2 aandoeningen |
| BCORBCL6 corepressor | Zelden (1–4%) | In 1 aandoening |
| FIP1L1factor interacting with PAPOLA and CPSF1 | Zelden (1–4%) | In 1 aandoening |
| IRF2BP2interferon regulatory factor 2 binding protein 2 | Zelden (1–4%) | In 1 aandoening |
| NABP1nucleic acid binding protein 1 | Zelden (1–4%) | In 1 aandoening |
| NPM1nucleophosmin 1 | Zelden (1–4%) | In 1 aandoening |
| NUMA1nuclear mitotic apparatus protein 1 | Zelden (1–4%) | In 1 aandoening |
| PMLPML nuclear body scaffold | Zelden (1–4%) | In 1 aandoening |
| PRKAR1Aprotein kinase cAMP-dependent type I regulatory subunit alpha | Zelden (1–4%) | In 1 aandoening |
| RARAretinoic acid receptor alpha | Zelden (1–4%) | In 1 aandoening |
| SLC34A2solute carrier family 34 member 2 | Zelden (1–4%) | In 1 aandoening |
| SLC5A1solute carrier family 5 member 1 | Zelden (1–4%) | In 1 aandoening |
| SPTBN1spectrin beta, non-erythrocytic 1 | Zelden (1–4%) | In 1 aandoening |
| STAT3signal transducer and activator of transcription 3 | Zelden (1–4%) | In 1 aandoening |
| STAT5Bsignal transducer and activator of transcription 5B | Zelden (1–4%) | In 1 aandoening |
| TBL1XR1TBL1X/Y related 1 | Zelden (1–4%) | In 1 aandoening |
| ZBTB16zinc finger and BTB domain containing 16 | Zelden (1–4%) | In 1 aandoening |
| C3complement C3 | Niet vastgelegd | In 1 aandoening |
| CD2APCD2 associated protein | Niet vastgelegd | In 1 aandoening |
| CD46CD46 molecule | Niet vastgelegd | In 1 aandoening |
| CFBcomplement factor B | Niet vastgelegd | In 1 aandoening |
| CFHcomplement factor H | Niet vastgelegd | In 1 aandoening |
| CFIcomplement factor I | Niet vastgelegd | In 1 aandoening |
| CLDN16claudin 16 | Niet vastgelegd | In 1 aandoening |
| FGAfibrinogen alpha chain | Niet vastgelegd | In 1 aandoening |
| GATA3GATA binding protein 3 | Niet vastgelegd | In 1 aandoening |
| GRHPRglyoxylate and hydroxypyruvate reductase | Niet vastgelegd | In 1 aandoening |
| HBBhemoglobin subunit beta | Niet vastgelegd | In 1 aandoening |
| LMNB2lamin B2 | Niet vastgelegd | In 1 aandoening |
| MMACHCmetabolism of cobalamin associated C | Niet vastgelegd | In 1 aandoening |
| NOTCH2notch receptor 2 | Niet vastgelegd | In 1 aandoening |
| NUP133nucleoporin 133 | Niet vastgelegd | In 1 aandoening |
| NUP93nucleoporin 93 | Niet vastgelegd | In 1 aandoening |
| PRDX1peroxiredoxin 1 | Niet vastgelegd | In 1 aandoening |
| SLC37A4solute carrier family 37 member 4 | Niet vastgelegd | In 1 aandoening |
| THBDthrombomodulin | Niet vastgelegd | In 1 aandoening |
| UMPSuridine monophosphate synthetase | Niet vastgelegd | In 1 aandoening |
Hoe vaak dit voorkomt bij mensen met een van de aandoeningen van het gen, de hoogste frequentie binnen die aandoeningen, zoals de Human Phenotype Ontology dit vastlegt. Deze pagina's beschrijven kenmerken en het onderzoek erachter; het zijn geen diagnose, en over symptomen kunt u het best een arts of genetisch adviseur raadplegen.
Smallere kenmerken
Bredere kenmerken
Waar dit vandaan komt
- De Human Phenotype Ontology, release 2026-09-01: het kenmerk, de namen, de definitie en de genen die ermee verbonden zijn. Meer informatie vindt u op hpo.jax.org.
- Gegevensrelease 2026.10.16-c6eea6bf.
Voor wie we er zijnOnze wetenschapProductenResultaten
InloggenVraagAan de slagvanaf $ 449
Eén test. Een leven lang antwoorden.
Vanaf $ 449Gratis verzending · Resultaten binnen 6–8 weken